Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50

AstraZeneca and Daiichi Sankyo win new breakthrough therapy designation for Enhertu

By Brian Buntz | April 27, 2022

AstraZeneca Daiichi-Sankyo Enhertu

AstraZeneca/Daiichi-Sankyo

The HER2-directed antibody-drug conjugate Enertu (trastuzumab deruxtecan) has won its fifth breakthrough therapy designation from the FDA.

Enhertu was developed jointly by AstraZeneca (LON:AZN) and Daiichi Sankyo (OTCMKTS: DSNKY).

The latest designation relates to treating adults with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-negative) breast cancer.

Of the five breakthrough therapy designations for the drug, three are for breast cancer, while the other two are in lung and gastric cancers, respectively.

In particular, the designation covers adults who have received prior systemic therapy for metastatic breast cancer or who have experienced disease recurrence within six months of finishing adjuvant chemotherapy.

In addition, the designation specifies that patients with hormone receptor (HR) positive breast cancer have received or be ineligible for endocrine therapy.

“Today’s news is a significant validation of the potential we see for the historic DESTINY-Breast04 trial to enable a paradigm shift in how breast cancer is classified by targeting the full spectrum of HER2 expression,” said Susan Galbraith, executive vice president, oncology R&D, AstraZeneca, in a statement. “Enhertu continues to show transformative potential, and this milestone represents an important advance for patients with HER2-low metastatic breast cancer who are in urgent need of new treatment options and better outcomes.”

At the beginning of the year, AstraZeneca and Daiichi Sankyo announced that the FDA accepted the supplemental Biologics License Application (sBLA) for Enhertu.

AZN shares were mostly flat, ticking up 0.17% to 10,350 pence, while Daiichi Sankyo shares were up 4%, hitting $23.72.


Filed Under: Oncology
Tagged With: AstraZeneca, breast cancer, Daiichi Sankyo, Enhertu, HER2, oncololgy
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Black Diamond Therapeutics
Black Diamond analysis highlights 22 new oncogenic HER2 driver mutations
AstraZeneca
Imfinzi with chemotherapy gets FDA priority review for locally advanced or metastatic biliary tract cancer
Novartis
Novartis reveals positive Phase 3 data for tislelizumab plus chemotherapy in esophageal cancer
Black Diamond Therapeutics
Black Diamond Therapeutics slashes workforce by 30% while discontinuing development of BDTX-189

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50